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Adventitial delivery minimizes the
proinflammatory effects of adenoviral
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Robert M. Driscoll, MS, and David A. Dichek, MD, San Francisco, Calif
Purpose: Adenovirus-mediated arterial gene transfer is a promising tool in the study of
vascular biology and the development of vascular gene therapy. However, intraluminal
delivery of adenoviral vectors causes vascular inflammation and neointimal formation.
Whether these complications could be avoided and gene transfer efficiency maintained
by means of delivering adenoviral vectors via the adventitia was studied. 
Methods: Replication-defective adenoviral vectors encoding a b -galactosidase (b -gal) gene
(AdRSVnLacZ) or without a recombinant gene (AdNull) were infused into the lumen
or the adventitia of rabbit carotid arteries. Two days after infusion of either
AdRSVnLacZ (n = 8 adventitial, n = 8 luminal) or AdNull (n = 4 luminal), recombinant
gene expression was quantitated by histochemistry (performed on tissue sections) and
with a b -gal activity assay (performed on vessel extracts). Inflammation caused by adeno-
virus infusion was assessed 14 days after infusion of either AdNull (n = 6) or vehicle (n
= 6) into the carotid adventitia. Inflammation was assessed by means of examination of
histologic sections for the presence of neointimal formation and infiltrating T cells and
for the expression of markers of vascular cell activation (ICAM-1 and VCAM-1). To
measure the systemic immune response to adventitial infusion of adenovirus, plasma
samples (n = 3) were drawn 14 days after infusion of AdNull and assayed for neutraliz-
ing antibodies.
Results: Two days after luminal infusion of AdRSVnLacZ, approximately 30% of lumi-
nal endothelial cells expressed b -gal. Similarly, 2 days after infusion of AdRSVnLacZ to
the adventitia, approximately 30% of adventitial cells expressed b -gal. b -gal expression
was present in the carotid adventitia, the internal jugular vein adventitia, and the vagus
nerve perineurium. Elevated b -gal activity (50- to 80-fold more than background; P <
.05) was detected in extracts made from all AdRSVnLacZ-transduced arteries. The
amount of recombinant protein expression per vessel did not differ significantly between
vessels transduced via the adventitia (17.1 mU/mg total protein [range, 8.1 to 71.5])
and those transduced via a luminal approach (10.0 mU/mg total protein [range, 3.9 to
42.6]). Notably, adventitial delivery of AdNull did not cause neointimal formation. In
addition, vascular inflammation in arteries transduced via the adventitia (ie, T-cell infil-
trates and ICAM-1 expression) was confined to the adventitia, sparing both the intima
and media. Antiadenoviral neutralizing antibodies were present in all rabbits after
adventitial delivery of AdNull.
Conclusion: Infusion of adenoviral vectors into the carotid artery adventitia achieves
recombinant gene expression at a level equivalent to that achieved by means of intralu-
minal vector infusion. Because adventitial gene transfer can be performed by means of
direct application during open surgical procedures, this technically simple procedure
may be more clinically applicable than intraluminal delivery. Moreover, despite the gen-
eration of a systemic immune response, adventitial infusion had no detectable patholog-
ic effects on the vascular intima or media. For these reasons, adventitial gene delivery
may be a particularly useful experimental and clinical tool. (J Vasc Surg 1999;29:•••.)
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Arterial gene transfer is currently used in a large
number of basic and preclinical investigations, both
as an experimental tool and as a potential means of
treating vascular disease. Because they can be pro-
duced in high titer and can mediate efficient gene
transfer into the normally quiescent cells of the
artery wall, adenoviral vectors have become the vec-
tor of choice for arterial gene transfer studies.1,2 The
promise that adenoviral vectors have shown in
inhibiting neointimal formation and thrombosis in
animal models of arterial injury make them particu-
larly attractive agents for the development of gene
therapy for human vascular disease.3-8
Despite their promise, adenoviral vectors have
detrimental effects on the artery wall that currently
limit their clinical and experimental usefulness.
Intraluminal infusion of adenoviral vectors into nor-
mal rabbit arteries causes neointimal formation, elic-
its a marked inflammatory response within the vas-
cular wall, and can cause both endothelial cell and
vasomotor dysfunction.9,10
Intraluminal infusion of adenoviral vectors also
provokes a strong humoral immune response to
adenoviral proteins, which prevents repeated aden-
ovirus-mediated gene transfer.11 Finally, to accom-
plish efficient intraluminal gene transfer, adenoviral
vectors must be allowed to dwell undisturbed in the
arterial lumen for approximately 20 minutes. During
this time, forward blood flow through the target
segment and its side branches must be interrupted.
The requirement to interrupt blood flow during
gene transfer may preclude intraluminal administra-
tion of adenoviral vectors to the coronary or cerebral
arteries, because these arteries supply territories that
have a relatively poor tolerance for ischemia.
Several groups have reported arterial gene trans-
fer by means of adventitial infusion of adenoviral vec-
tors to be an alternative to intraluminal administra-
tion.12-15 These studies established that adventitial
gene transfer was feasible and could be accomplished
without interruption of blood flow. One study also
demonstrated that adventitial gene transfer of a bio-
logically active molecule (endothelial nitric oxide
synthase) could alter the arterial phenotype in a
potentially therapeutic manner. Despite these
promising results, the effects of adventitial gene
transfer on the arterial phenotype have not been
explored completely. Specifically, it is not yet clear
whether adventitial gene transfer might accomplish
significant levels of recombinant protein expression
while avoiding the intimal and medial lesions that are
associated with intraluminal adenovirus infusion.
We established a model of adenoviral gene
transfer to the adventitia of the rabbit common
carotid artery. We compared the efficiency of
adventitial delivery with that of intraluminal deliv-
ery and studied whether adventitial infusion of ade-
novirus causes neointimal formation and vascular
inflammation.
METHODS
Adenoviral vectors. Two adenoviral vectors
were used in this study: AdRSVnLacZ and AdNull.
AdRSVnLacZ is an E1- and E3-deleted, replication-
defective adenovirus that contains a nuclear-targeted
Escherichia coli b -galactosidase (b -gal) transgene dri-
ven by the Rous sarcoma virus (RSV) long terminal
repeat promoter.16 AdNull is of identical structure
to AdRSVnLacZ, except that the RSV-b -gal expres-
sion cassette is omitted.17 Propagation, purification,
and storage of these vectors were performed as
described.18 Titers of viral stocks used in the present
experiments, determined by plaque titration on 293
cells, ranged from 2 – 6 · 10l0 plaque-forming units
(pfu)/mL. Ratios of total viral particles (determined
by OD260)19 to pfu were less than 75 for all viral
stocks. The absence of replication-competent virus
was confirmed by a polymerase chain reaction-based
assay that is capable of detecting one E1a-containing
virus genome per 1 · 106 vector genomes.
For animal experiments, frozen vector stocks were
used within 30 minutes of thawing. Vector stocks
were diluted in Dulbecco’s modified Eagle’s medium
(DMEM) containing 1 mg/mL rabbit serum albu-
min to achieve a final concentration of 5 · 109
pfu/mL. As a control, some arteries were infused
with a “vehicle” solution consisting of virus storage
buffer (10 mmol/L Tris-HCl, pH 7.4, 1 mmol/L
MgCl2, and 10% glycerol) diluted in DMEM con-
taining 1 mg/mL rabbit serum albumin.
Animal experiments. Both common carotid
arteries of 16 male New Zealand white rabbits (2.5
to 3.5 kg) were used (n = 32 arteries). Animals were
housed individually in stainless steel, wire-bottomed
cages in a room with a 12-hour light-dark cycle. They
were sedated with intramuscular injections of keta-
mine (50 mg/kg) and xylazine (3 mg/kg). After
endotracheal intubation, anesthesia was maintained
with inhaled halothane (2%). For infection prophy-
laxis, animals received enrofloxacin (2.27%, 0.2
mL/kg, intramuscularly) before the skin incision.
For intraluminal vector administration, both
common carotid arteries were exposed through a
midline cervical incision, and the single side branch
from each artery was coagulated and divided with an
electrosurgical unit (Macan, Chicago, Ill). After
JOURNAL OF VASCULAR SURGERY
544 Schneider et al March 1999
intravenous administration of heparin (100 U/kg),
the common carotid artery was isolated between
atraumatic vascular clamps, and a 24-g catheter
(Jelco, Critikon, Tampa, Fla) was introduced
through an arteriotomy in the proximal common
carotid. The isolated vessel segment was washed free
of blood with 1 mg/mL rabbit serum albumin in
DMEM, and the catheter was secured in place with
a single 5-0 silk ligature. Approximately 200 m L of
vector or vehicle solution was infused to distend the
vessel segment to its normal physiologic caliber.
After a 20-minute incubation period, the vector
solution was removed by means of aspiration into
the catheter. Back-bleeding into the catheter was
also performed to minimize systemic administration
of virus. After removal of the catheter and silk tie,
the arteriotomy was repaired with 7-0 prolene
suture, and flow was restored. An identical proce-
dure was performed on the contralateral carotid
artery, and the cervical wound was closed. This pro-
tocol is essentially the same as that used in an earlier
study to examine the effect of adenoviral infusion on
normal rabbit femoral arteries.9 In the earlier study,
however, the vector infusate was not aspirated, but
released to the systemic circulation after the incuba-
tion period.
For adventitial administration of adenovirus,
both carotid sheaths were exposed through a mid-
line cervical incision. A 30-g needle was inserted
into the periarterial space between the sheath and
common carotid artery, and 200 m L of virus or con-
trol solution was infused. As the solution was inject-
ed, the needle was gently advanced, distending the
periarterial sheath to a length of 3 cm. An identical
procedure was performed on the contralateral
carotid artery, and the cervical wound was closed.
Animals were killed by means of pentobarbital
overdose either 2 or 14 days after gene transfer.
Excised arteries were immersion fixed or snap frozen
in liquid nitrogen and embedded in OCT (optimal
cutting temperature) compound (Miles, Elkhart,
Ind).
Experimental protocols were approved by the
University of California, San Francisco, Committee
on Animal Research and conformed to the guide-
lines published in the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal
Resources, Commission on Life Sciences, National
Research Council. Washington: National Academy
Press, 1996).
Histochemical detection of b -gal expression
and measurement of b -gal activity. AdRSVnLacZ
was delivered to the lumen (n = 4) or the adventitia 
(n = 4) of carotid arteries, and transgene expression
was assessed by means of histochemical staining 2 days
after gene transfer. Excised vessels were opened longi-
tudinally, washed in phosphate-buffered saline, and
immersed in 2% formaldehyde and 0.2% glutaralde-
hyde for 2 hours at room temperature. Vessels were
then incubated in 5-bromo-4-chloro-3-indolyl-b -D-
galactopyranoside (X-gal) for 2 hours at 37°C. Stained
vessels were examined en face for punctate nuclear blue
staining and were then divided into five to eight rings,
which were embedded in paraffin. Cross sections (5
m m thick) were cut and counterstained with nuclear-
fast red. Sections were examined by means of light
microscopy to identify cells expressing b -gal.
b -gal activity was measured in extracts of arteries
harvested 2 days after delivery of AdRSVnLacZ to
the carotid artery lumen (n = 4) and either AdNull
(n = 4) or AdRSVnLacZ (n = 4) to the adventitia, as
described.20 All samples were assayed in duplicate.
Evaluation of local vascular inflammation and
neointima formation. To assess potential proinflam-
matory effects of adventitial infusion, we infused
AdNull into the adventitia of six carotid arteries. We
used AdNull instead of AdRSVnLacZ to eliminate the
possibility of a confounding inflammatory response to
the foreign b -gal protein.21-23 To control for the
effects of the surgical procedure alone, we infused
vehicle into the adventitia of two carotid arteries. In
parallel with these studies, we carried out a separate
series of experiments aimed at elucidating the interplay
between cholesterol feeding and luminal adenovirus
infusion (Schneider et al, manuscript in preparation).
In this separate series of experiments, we infused
AdNull in the lumen of rabbit carotid arteries and eval-
uated the inflammatory response. To avoid both
redundant animal experiments (prohibited by our ani-
mal-use protocol) and repeating the publication of
data, we are not reporting these specific results; how-
ever, we refer to them as “unpublished observations.”
Fourteen days after vector infusion (a time at which
adenovirus-induced vascular inflammation is fully
developed9), vessels were excised, rinsed in phosphate-
buffered saline, cut into four rings, and snap frozen in
OCT compound. Serial cryosections were air-dried,
fixed in acetone at –20°C for 5 minutes, incubated
with 0.4% hydrogen peroxide, and preincubated with
10% normal horse serum. Primary monoclonal anti-
bodies diluted in 10% normal horse serum were incu-
bated at room temperature for two hours, followed 
by biotinylated secondary antibody (diluted 1:100)
and avidin-biotin horseradish peroxidase complex
(Vectastain ABC Elite kit, Vector Laboratories).
Immunoreactivity was visualized with 3-amino-9-ethyl
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carbazole, and cross sections were counterstained with
hematoxylin. Immunohistochemical staining was per-
formed with a series of three monoclonal antibodies:
KEN-5, which recognizes the CD5 antigen on rabbit
T cells (diluted 1:25; Spring Valley Laboratories,
Woodbine, Md); Rb1/9, which recognizes rabbit
VCAM-1 (diluted 1:50; a gift from Dr Myron
Cybulsky, Boston, Mass); and Rb2/3, which recog-
nizes rabbit ICAM-1 (diluted 1:200; a gift from Dr
Myron Cybulsky). Rabbit spleen was stained as a pos-
itive control for T cells and VCAM-1 and ICAM-1
expression, and the specificity of immunoreactivity was
confirmed by means of both omission of the primary
antibody and substitution of isotype-matched antibod-
ies for the primary antibody. In addition, four evenly
spaced cryosections from each vessel were examined
for the presence of a neointima.
Neutralizing antiadenoviral antibody assay.
Neutralizing serum antibodies to adenovirus type 5
were assayed at 14 days after virus infusion, as
described.11
Statistics. b -gal activity measurements were not
normally distributed and are reported as the median
and range. Groups were compared with the Kruskal-
Wallis one-way analysis of variance, with pairwise
comparisons made with the Student-Newman-Keuls
test.24 Differences were considered significant if P
was less than .05. The term “n” refers to arteries.
RESULTS
Morbidity and mortality of adventitial gene
transfer. There were no intraoperative or postoper-
ative deaths, and all vessels were patent when the
animals were killed.
Localization of recombinant gene expression.
All vessels harvested 2 days after delivery of
AdRSVnLacZ to either the lumen or the adventitia
stained positively with X-gal. It was revealed by
means of microscopic examination of sections taken
from vessels that received AdRSVnLacZ intralumi-
nally (n = 4) that b -gal expression was largely con-
fined to endothelial cells. b -gal expression was also
seen in occasional adventitial cells, which may be
caused by either spillage of vector solution during the
gene transfer procedure or transport of the vector to
vasa vasorum.25 Approximately 30% of luminal
endothelial cells demonstrated b -gal expression (Fig
1A). In contrast, after adventitial delivery of
AdRSVnLacZ (n = 4) b -gal expression was confined
to the adventitia (ie, there was no expression in the
media or endothelium), with approximately 30% of
adventitial cells staining blue (Fig 1B). The b -gal-
expressing cells in the adventitia appeared to be
fibroblasts, as judged both by their spindle-shaped
morphology and by the absence of markers for
smooth muscle cells (smooth muscle a actin),26 T
cells (CD5),27 and macrophages (RAM-11).28
Fibroblast-like cells expressing b -gal were also seen in
other structures within the carotid sheath, including
the adventitia of the internal jugular vein and the per-
ineurium of the vagus nerve (not shown).
Efficiency of gene transfer. Two days after
gene transfer, extracts of arteries infused intralumi-
nally with AdNull contained low-level endogenous
b -gal activity (0.21 mU/mg protein [range, 0.15 to
0.32]; Fig 2). In contrast, b -gal activity in extracts of
arteries infused intraluminally with AdRSVnLacZ
was almost 50-fold higher (10.0 mU/mg protein
[range, 3.9 to 42.6]; P < .05 vs AdNull-infused
arteries). Arteries transduced with AdRSVnLacZ via
the adventitia also contained elevated b -gal activity
(17.1 mU/mg protein [range, 8.1 to 71.5]). This
activity was significantly more than that present in
the AdNull arteries (P < .05) and was essentially
equivalent to that present in extracts of arteries
infused intraluminally with AdRSVnLacZ (P = NS).
Local vascular inflammation and neointimal
formation after adventitial infusion of adenoviral
vectors. Histologic sections from arteries (n = 6)
infused via the adventitia with vehicle alone contained
virtually no T cells (Fig 1C) and displayed only low-
level expression of ICAM-1 (Fig 1D). There was no
expression of VCAM-1 in these sections (not shown).
In contrast, sections from all arteries (n = 6) in which
AdNull was infused into the adventitia had substantial
T-cell infiltrates and ICAM-1 expression in the adven-
titia and perivascular tissues (Fig 1E,F). No VCAM-1
expression was detected in sections from arteries
infused via the adventitia with AdNull. T-cell infil-
trates and ICAM-1 expression were confined to the
adventitia and were not present in the media or inti-
ma of AdNull-infused arteries.
Frozen sections were also examined for the pres-
ence of a neointima. No neointima was observed in
any carotid artery after adventitial delivery of either
AdNull or vehicle. In contrast, we invariably observe
neointimal lesion formation and T-cell infiltrates,
VCAM-1, and ICAM-1 expression in the media and
intima of all rabbit arteries infused intraluminally with
AdNull9 (unpublished observations, D. Schneider).
Humoral immune response. Neutralizing
antiadenoviral antibodies were undetectable both
before adenovirus infusion and at 14 days after
adventitial delivery of vehicle alone. Fourteen days
after adventitial delivery of AdNull, neutralizing
antiadenoviral antibodies were present in the sera of
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all rabbits (n = 3; titers equal to 1:512 or greater).
These titers are similar to those we have measured
after intraluminal delivery of adenoviral vectors in
both rats11 and rabbits (D. Schneider, unpublished
observations).
DISCUSSION
The major goals of this study were to investigate
the efficiency of adenovirus-mediated gene transfer
to the adventitia and to determine whether adventi-
tial infusion causes vascular inflammation and neoin-
timal formation. Our major findings were: (1)
adventitial infusion resulted in substantial recombi-
nant gene expression, comparable with levels
achieved by means of intraluminal virus infusion;
and (2) adventitial infusion caused inflammation
that was limited to the adventitia and was not asso-
ciated with neointimal lesion formation.
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Fig 1. Histochemical and histologic characterization of adenovirus-transduced arteries. A and
B, b -gal transgene expression is detected in paraffin sections taken from arteries 2 days after
infusion of AdRSVnLacZ either intraluminally (A) or via the adventitia (B). Transgene expres-
sion is largely confined to the endothelium and adventitia, respectively. C and D, Minimal
inflammation is detected after adventitial infusion of vehicle only. Sections taken from arteries
14 days after vehicle infusion and stained for T cells (C) or ICAM-1 (D) showed virtually no T
cells and low-level ICAM-1 expression. E and F, Substantial inflammation is detected after
adventitial infusion of AdNull. Sections taken from arteries 14 days after adventitial infusion of
AdNull contained numerous T cells (E) and high-level ICAM-1 expression (F). Vascular inflam-
mation is confined to the adventitia, and no neointima is present. Paraffin sections were stained
with X-gal and counterstained with nuclear-fast red (A, B). Cryosections were stained with spe-
cific antibodies and counterstained with hematoxylin (C to F). The internal elastic lamina is
indicated by arrowheads. Lu, Lumen; Ad, adventitia. (Original magnification · 100)
By delivering adenoviral vectors via the adventi-
tia instead of the lumen, we avoided vector-induced
neointimal formation. This result contrasts with our
previous work, in which luminal infusion of aden-
oviral vectors caused neointimal growth.9 In this
previous work, we demonstrated that neointimal
formation was caused by the adenovirus, not by the
surgical procedure of clamping and arteriotomy,
because we found no significant neointimal forma-
tion in control arteries that underwent clamping,
arteriotomy, and infusion of buffer only. Our present
results, therefore, suggest that it may be possible to
use adenoviral vectors to deliver therapeutic genes to
blood vessels without promoting vascular lesion for-
mation. Although our results obtained with normal
arteries are encouraging, these results should be
extrapolated to diseased arteries only with caution.
The cytokines produced by inflammatory T cells in
the adventitia of adenovirus-transduced arteries
could promote lesion progression in vessels with
established lesions.29 This possibility will require
testing in animal models of arterial disease.
Gene transfer to the adventitia may be therapeu-
tically useful. Because adventitial gene transfer is as
efficient as luminal gene transfer and can be per-
formed more rapidly and without interruption of
blood flow, adventitial gene transfer may be particu-
larly useful in vascular beds (eg, the coronary or
cerebral circulation) in which even a brief interrup-
tion of blood flow can have serious consequences.
Although the adventitia is often viewed as a relative-
ly inert coating of the more biologically active media
and intima, the adventitia may play an important role
in the development of vascular disease. Recent stud-
ies have shown that loss of compensatory remodel-
ing, as opposed to intimal hyperplasia, may be the
critical determinant of luminal narrowing in resteno-
sis and atherosclerosis.30 The adventitia appears to
play a prominent role in directing vessel wall remod-
eling. For example, after balloon injury, adventitial
myofibroblasts migrating into the neointima may
contribute to vascular remodeling and luminal
loss.31-33 In addition, several secreted gene products
that may contribute to intimal lesion formation are
expressed in the adventitia after balloon injury,
including plasminogen activator inhibitor type 1,34
transforming growth factor-b 1,35 and tissue factor.36
Expression of recombinant proteins after gene trans-
fer to the adventitia may provide a powerful means of
antagonizing the effects of these potential mediators
of lesion formation.
Adventitial gene transfer could also be used as a
means of expressing proteins that produce a thera-
peutic effect directly on the vascular intima or media
(ie, the sites of the most common vascular diseases).
The concept that adventitial delivery of therapeutic
molecules may affect both the endothelium and the
media is well established.12,37 Moreover, in athero-
sclerotic vessels, branches of vasa vasorum extend
from the adventitia into intimal plaques.38 This
anatomic substrate could allow transgene products
expressed in the adventitia to be effectively trans-
ported to sites of intimal disease. Nevertheless, it
must be recognized that adventitial gene transfer
will be most useful for the expression of molecules
that can diffuse into the artery wall. The ability of
adventitial gene transfer to counteract important
pathological vascular processes that begin at the level
of the endothelium will require further experimental
verification.
Although our data demonstrate significant ther-
apeutic potential for adventitial gene transfer, we
emphasize that important unresolved problems
remain associated with the vascular infusion of ade-
noviral vectors. One of these problems is the sub-
stantial tissue inflammation produced by adenoviral
vectors. We found adventitial accumulation of T
cells and up-regulation of ICAM-1. The long-term
consequences of this adventitial inflammation are
unknown; however, adventitial inflammation is a
prominent feature of several human vascular disor-
ders, including inflammatory aneurysms, Takayasu’s
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Fig 2. b -gal activity in carotid artery extracts after intra-
luminal and adventitial gene transfer. Infusates containing
5 · 109 pfu/mL of AdNull or AdRSVnLacZ were deliv-
ered via the lumen or adventitia, as indicated. Arteries
were harvested 2 days after gene transfer, and b -gal activ-
ity was measured in the vessel lysates. Each data point rep-
resents one artery, and the bar represents the median b -gal
activity for each group.
arteritis, and Behçet’s disease.39 Other hurdles that
must be overcome to optimize the clinical usefulness
of adenoviral gene transfer include the limited dura-
tion of transgene expression9 and the barriers to
gene transfer that are posed by the high prevalence
in the human population of preexisting humoral and
cellular immunity to adenoviral antigens.11,40
In summary, adenoviral vectors can achieve effi-
cient recombinant gene expression after infusion
into the arterial adventitia, while minimizing poten-
tially deleterious side effects. Although these find-
ings increase the likelihood that arterial gene trans-
fer with adenoviral vectors will eventually be clinical-
ly useful, additional studies are required to
determine the effects of adventitial gene transfer in
arteries with preexisting disease and to identify gene
products that mediate therapeutic effects when
expressed in the adventitia. If these future studies
continue to produce promising results, adventitial
gene transfer may eventually provide a means of
treating peripheral vascular diseases such as resteno-
sis and bypass graft failure.
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REFERENCES
1. Nabel EG. Gene therapy for cardiovascular disease.
Circulation 1995;91:541-8.
2. Dichek DA. Interventional approaches to the introduction of
genetic material into the cardiovascular system. In: Topol EJ,
editor. Textbook of interventional cardiology. 3rd ed.
Philadelphia: WB Saunders; 1999. p. 703-24.
3. Ohno T, Gordon D, San H, Pompili VJ, Imperiale MJ, Nabel
GJ, et al. Gene therapy for vascular smooth muscle cell pro-
liferation after arterial injury. Science 1994;265:781-4.
4. Chang MW, Barr E, Seltzer J, Jiang Y-Q, Nabel GJ, Nabel
EG, et al. Cytostatic gene therapy for vascular proliferative
disorders with a constitutively active form of the retinoblas-
toma gene product. Science 1995;267:518-22.
5. Rade JJ, Schulick AH, Virmani R, Dichek DA. Local aden-
oviral-mediated expression of recombinant hirudin reduces
neointimal formation after arterial injury. Nat Med 1996;
2:293-8.
6. Zoldhelyi P, McNatt J, Xu X-M, Loose-Mitchell D, Meidell
RS, Clubb FJ Jr, et al. Prevention of arterial thrombosis by
adenovirus-mediated transfer of cyclooxygenase gene.
Circulation 1996;93:10-7.
7. Chen D, Krasinski K, Chen D, Sylvester A, Chen J, Nisen
PD, et al. Downregulation of cyclin-dependent kinase 2
activity and cyclin A promoter activity in vascular smooth
muscle cells by p27KIP1, an inhibitor of neointima formation
in the rat carotid artery. J Clin Invest 1997;99:2334-41.
8. Hedin U, Wahlberg E. Gene therapy and vascular disease:
Potential applications in vascular surgery. Eur J Vasc
Endovasc Surg 1997;13:101-11.
9. Newman KD, Dunn PF, Owens JW, Schulick AH, Virmani
R, Sukhova G, et al. Adenovirus-mediated gene transfer into
normal rabbit arteries results in prolonged vascular cell acti-
vation, inflammation, and neointimal hyperplasia. J Clin
Invest 1995;96:2955-65.
10. Lafont A, Loirand G, Pacaud P, Vilde F, Lemarchand P,
Escande D. Vasomotor dysfunction early after exposure of
normal rabbit arteries to an adenoviral vector. Hum Gene
Ther 1997;8:1033-40.
11. Schulick AH, Vassalli G, Dunn PF, Dong G, Rade JJ,
Zamarron C, et al. Established immunity precludes aden-
ovirus-mediated gene transfer in rat carotid arteries. Potential
for immunosuppression and vector engineering to overcome
barriers of immunity. J Clin Invest 1997;99:209-19.
12. Kullo IJ, Mozes G, Schwartz RS, Gloviczki P, Crotty TB,
Barber DA, et al. Adventitial gene transfer of recombinant
endothelial nitric oxide synthase to rabbit carotid arteries
alters vascular reactivity. Circulation 1997;96:2254-61.
13. Ooboshi H, Welsh MJ, Rios CD, Davidson BL, Heistad DD.
Adenovirus-mediated gene transfer in vivo to cerebral blood
vessels and perivascular tissue. Circ Res 1995;77:7-13.
14. Ríos CD, Ooboshi H, Piegors D, Davidson BL, Heistad DD.
Adenovirus-mediated gene transfer to normal and atheroscle-
rotic arteries. A novel approach. Arterioscler Thromb Vasc
Biol 1995;15:2241-5.
15. Laitinen M, Pakkanen T, Donetti E, Baetta R, Luoma J,
Lehtolainen P, et al. Gene transfer into the carotid artery using
an adventitial collar: Comparison of the effectiveness of the
plasmid-liposome complexes, retroviruses, pseudotyped retro-
viruses, and adenoviruses. Hum Gene Ther 1997;8:1645-50.
16. Dong G, Schulick AH, DeYoung MB, Dichek DA.
Identification of a cis-acting sequence in the human plas-
minogen activator inhibitor type-1 gene that mediates trans-
forming growth factor-b 1 responsiveness in endothelium in
vivo. J Biol Chem 1996;271:29969-77.
17. Kang S-M, Schneider DB, Lin Z, Hanahan D, Dichek DA,
Stock PG, et al. Fas ligand expression in islets of Langerhans
does not confer immune privilege and instead targets them
for rapid destruction. Nat Med 1997;3:738-43.
18. Lee SW, Trapnell BC, Rade JJ, Virmani R, Dichek DA. In
vivo adenoviral vector-mediated gene transfer into balloon-
injured rat carotid arteries. Circ Res 1993;73:797-807.
19. Mittereder N, March KL, Trapnell BC. Evaluation of the
concentration and bioactivity of adenovirus vectors for gene
therapy. J Virol 1996;70:7498-509.
20. Schulick AH, Newman KD, Virmani R, Dichek DA. In vivo
gene transfer into injured carotid arteries. Optimization and
evaluation of acute toxicity. Circulation 1995;91:2407-14.
21. Roessler BJ, Allen ED, Wilson JM, Hartman JW, Davidson
BL. Adenoviral-mediated gene transfer to rabbit synovium in
vivo. J Clin Invest 1993;92:1085-92.
22. Gao G-P, Yang Y, Wilson JM. Biology of adenovirus vectors
with E1 and E4 deletions for liver-directed gene therapy. J
Virol 1996;70:8934-43.
23. Van Ginkel FW, Liu C, Simecka JW, Dong J-Y, Greenway T,
Frizzell RA, et al. Intratracheal gene delivery with adenoviral
vector induces elevated systemic IgG and mucosal IgA anti-
bodies to adenovirus and b -galactosidase. Hum Gene Ther
1995;6:895-903.
24. Zar JH. Biostatistical analysis. Englewood Cliffs (NJ):
Prentice-Hall; 1984.
25. Rome JJ, Shayani V, Flugelman MY, Newman KD, Farb A,
Virmani R, et al. Anatomic barriers influence the distribution
of in vivo gene transfer into the arterial wall. Modeling with
JOURNAL OF VASCULAR SURGERY
Volume 29, Number 3 Schneider et al 549
microscopic tracer particles and verification with a recombi-
nant adenoviral vector. Arterioscl Thromb 1994;14:148-61.
26. Tsukada T, Tippens D, Gordon D, Ross R, Gown AM.
HHF35, a muscle-actin-specific monoclonal antibody. I.
Immunocytochemical and biochemical characterization. Am
J Pathol 1987;126:51-60.
27. Drew AF, Tipping PG. T helper cell infiltration and foam cell
proliferation are early events in the development of athero-
sclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc
Biol 1995;15:1563-8.
28. Tsukada T, Rosenfeld M, Ross R, Gown AM. Immuno-
cytochemical analysis of cellular components in atheroscle-
rotic lesions. Use of monoclonal antibodies with the
Watanabe and fat-fed rabbit. Arteriosclerosis 1986;6:601-13.
29. Schneider DB, Fly CA, Dichek DA, Geary RL. Adenoviral
gene transfer in arteries of hypercholesterolemic nonhuman
primates. Hum Gene Ther 1998;9:815-21.
30. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R,
Kolettis GJ. Compensatory enlargement of human athero-
sclerotic coronary arteries. N Engl J Med 1987;316:1371-5.
31. Shi Y, Pieniek M, Fard A, O’Brien J, Mannion JD, Zalewski
A. Adventitial remodeling after coronary arterial injury.
Circulation 1996;93:340-8.
32. Shi Y, O’Brien JE Jr, Fard A, Mannion JD, Wang D, Zalewski
A. Adventitial myofibroblasts contribute to neointimal for-
mation in injured porcine coronary arteries. Circulation
1996;94:1655-64.
33. Scott NA, Cipolla GD, Ross CE, Dunn B, Martin FH,
Simonet L, et al. Identification of a potential role for the
adventitia in vascular lesion formation after balloon over-
stretch injury of porcine coronary arteries. Circulation
1996;93:2178-87.
34. Sawa H, Lundgren C, Sobel BE, Fujii S. Increased intramur-
al expression of plasminogen activator inhibitor type 1 after
balloon injury: A potential progenitor of restenosis. J Am
Coll Cardiol 1994;24:1742-8.
35. Shi Y, O’Brien JE Jr, Fard A, Zalewski A. Transforming
growth factor- b 1 expression and myofibroblast formation
during arterial repair. Arterioscl Thromb Vasc Biol 1996;
16:1298-1305.
36. Marmur JD, Rossikhina M, Guha A, Fyfe B, Friedrich V,
Mendlowitz M, et al. Tissue factor is rapidly induced in arte-
rial smooth muscle after balloon injury. J Clin Invest
1993;91:2253-9.
37. Simons M, Edelman ER, DeKeyser J-L, Langer R,
Rosenberg RD. Antisense c-myb oligonucleotides inhibit inti-
mal arterial smooth muscle cell accumulation in vivo. Nature
1992;359:67-70.
38. Zhang Y, Cliff WJ, Schoefl GI, Higgins G. Immuno-
histochemical study of intimal microvessels in coronary ath-
erosclerosis. Am J Pathol 1993;143:164-72.
39. Virmani R, Farb A, Burke A. Atlas of Cardiovascular
Pathology. Philadelphia: WB Saunders;1996.
40. Flomenberg P, Piaskowski V, Truitt RL, Casper JT.
Characterization of human proliferative T cell responses to
adenovirus. J Infect Dis 1995;171:1090-6.
Submitted May 1, 1998; accepted Aug 14, 1998.
JOURNAL OF VASCULAR SURGERY
550 Schneider et al March 1999
TABLE OF CONTENTS BY E-MAIL
To receive the tables of contents by e-mail, send an e-mail message to:
majordomo@mosby.com
Leave the subject line blank, and type the following as the body of your message:
Subscribe jvs_toc 
You can also sign up through our website at:
http:www.mosby.com/jvs
You will receive an e-mail to confirm that you have been added to the mailing list. 
Note that TOC e-mails will be sent out when a new issue is posted to the web site.
